Biogen has been granted a patent for compounds of Formula (I’) for the treatment of disorders responsive to the inhibition of apoptosis signal-regulating kinase 1 (ASK1). The patent includes compounds of Formulas (I), (II), (III), (IIIA), and (IIIB), along with methods for their use and production. GlobalData’s report on Biogen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Biogen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Biogen, Personalized cancer vaccines was a key innovation area identified from patents. Biogen's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11897898B2) discloses a compound represented by Formula (F) and Formula (II), with specific variations in the structure denoted by L and R groups. The compound is designed to target apoptosis signal-regulating kinase 1 (ASK1) for the treatment of disorders, particularly autoimmune conditions like multiple sclerosis. The patent claims cover a range of structural modifications within the compound, including substitutions in alkyl, alkylene, and heterocyclyl groups, aimed at enhancing the therapeutic efficacy of the compound.

Furthermore, the patent includes claims for pharmaceutical compositions containing the disclosed compound and methods for treating ASK1-related disorders by administering the compound to subjects in need. The focus on autoimmune disorders, specifically multiple sclerosis, highlights the potential of the compound in addressing complex medical conditions. The detailed structural variations outlined in the patent claims provide a roadmap for further research and development in the field of ASK1 inhibition, offering new possibilities for therapeutic interventions in autoimmune diseases.

To know more about GlobalData’s detailed insights on Biogen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies